Non-Hodgkin Lymphoma | Topics

Odronextamab Shows Promise in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
December 06, 2020

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Combined HDAC, mTOR Inhibition Shows Clinical Efficacy in Relapsed/Refractory Hodgkin Lymphoma
October 15, 2020

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 07, 2020

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.